News

New Ultra-Sensitive Amp’d™ HSP70 ELISA Kit for Detection of Baseline and Upregulated Levels of HSP70

Enzo Life Sciences, Inc. Strengthening our leadership position in heat shock and stress related products, Enzo Life Sciences now offers Amp’d™ HSP70 High Sensitivity ELISA Kit – the most sensitive ELISA for Hsp70 detection. This kit enables detection of both baseline and upregulated levels of Hsp70 (Hsp72) and relies on small amounts of starting sample. Hsp70, a major molecular chaperone and large heat shock protein, plays a role in cell stress regulation, folding/re-folding of substrate proteins, preventing aggregation, and many…

APP ΔC31 ELISA Kit from Enzo Life Sciences, Inc. for the Quantification of a Novel APP Cleavage Fragment Associated with Alzheimer’s Disease

Enzo Life Sciences, Inc APP ΔC31 ELISA Kit from Enzo Life Sciences, Inc. for the Quantification of a Novel APP Cleavage Fragment Associated with Alzheimer’s Disease Further establishing its position as an innovator in tools for detection of neurodegenerative diseases, Enzo offers a high sensitivity APP ΔC31 ELISA Kit; a one-of-a-kind quantitative ELISA for Alzheimer’s research . Unlike the more familiar β-amyloid and tau fibrillar pathway leading to amyloid plaques and tangles, APP ΔC31 reveals an alternative, unique pro-apoptotic mechanism…

NeoStem Expands Treg International Patent Portfolio with Granting of Patent in Japan

NeoStem, Inc. New York, February 4, 2014 – NeoStem, Inc. (NASDAQ:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy industry, today announced the expansion of intellectual property protection surrounding the Company’s T-regulatory cell (“Treg”) program with the grant of Japanese Patent Number 5409827 titled “Methods for the Isolation and Expansion of Cord Blood Derived T Regulatory Cells.” This grant further expands the scope and reach of NeoStem’s Treg patent estate internationally. Through its Treg program, NeoStem is…

Sartorius appoints internationally experienced laboratory manager to join its top management team

Sartorius Michael Melingo to succeed Dominique Baly in the Sartorius lab business Goettingen, January 30, 2014 – Effective April 1, 2014, Michael Melingo will head marketing, sales and services of the Lab Products & Services Division at Sartorius. He will therefore succeed Dominique Baly, who will retire from the company as planned after reaching retirement age. Michael Melingo will report to CEO and Executive Board Chairman Dr. Joachim Kreuzburg and be a member of the Group Executive Committee, the highest…

EMD Millipore Expands its EMPROVE Raw Materials Portfolio to 400 Products

EMD Millipore • Portfolio now includes 400 active pharmaceutical ingredients, excipients and biopharmaceutical materials • Application-specific documentation streamlines pharmaceutical process and reduces qualification costs • Increases patient safety by avoiding errors inherent in manual documentation Billerica, MA – EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced the expansion of its EMPROVE® raw materials portfolio to 400 active pharmaceutical ingredients, excipients and biopharmaceutical materials. The products offer comprehensive application-specific documentation in addition to superior quality,…

Quattroflow to Highlight Single-Use Benefits of Quaternary Diaphragm Pumps at INTERPHEX 2014

Quattroflow, part of Pump Solutions Group Quattroflow™ to Highlight Single-Use Benefits of Quaternary Diaphragm Pumps at INTERPHEX 2014 Kamp-Lintfort, Germany, January 22, 2014 — Quattroflow™, part of Pump Solutions Group (PSG®) and a leading brand of positive displacement quaternary diaphragm pumps for the biopharmaceutical industry, has announced that it will display the latest offerings in its line of pumps for use in pharmaceutical and biologic-handling applications at INTERPHEX 2014 in Booth No. 2633. The INTERPHEX Show, which brings together a…

KDG Acquires Marcor to Enter Bio and Nutraceuticals Market

KODA Distribution Group Marcor Development Corp., a New Jersey-based distributor for more than 35 years of specialty chemicals and naturally derived ingredients for use in nutraceuticals, biologicals, pharmaceuticals and related applications, announced that it is being acquired by KODA Distribution Group (KDG), the leading US specialty chemical distributor. Marcor will maintain its current management and staff, operating from its Carlstadt, NJ headquarters. Charles Garbarini, President, noted “we welcome the opportunity to be the foundation of KDG’s growth into these markets…

Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with MedImmune

Lonza and BioWa BioWa, Inc. and Lonza today announced that they have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. MedImmune has licensed the companies’ POTELLIGENT® CHOK1SV Cell Line Technology for use in multiple proprietary antibodies in its pipeline. POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza’s industry leading GS Gene Expression System™. The…

NeoStem Subsidiary Progenitor Cell Therapy Announces Cell Therapy Manufacturing Collaboration with ATMI

NeoStem, Inc. November 4, 2013 New York, NY. NeoStem, Inc. (NASDAQ: NBS), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), an internationally recognized contract development and manufacturing organization, announced today that PCT has entered into a collaboration with ATMI, Inc. (NASDAQ: ATMI), a global technology company and leader in single-use bioprocess solutions. As industry leaders, PCT and ATMI will collaborate on a non-exclusive basis enabling PCT and PCT’s affiliates to offer to…

DSM Celebrates Opening of New cGMP Facility for Biopharmaceutical Manufacturing in Brisbane, Australia

DSM Pharmaceutical Products DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), today officially opens its new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia. The facility was built in partnership with Biopharmaceuticals Australia with cooperation from the government of Queensland and the Commonwealth of Australia. This world-class operation in the Asia-Pacific region is an important growth area in DSM’s strategic development in the biopharmaceutical field. The facility was designed by an…